跳至主要内容
临床试验/DRKS00032193
DRKS00032193已完成Unknown

In vivo evaluation of coated hard capsules for site-specific drug delivery

Institut für Pharmazie - Biopharmazie und Pharmazeutische Technologie0 个研究点目标入组 12 人开始时间: 2023年7月28日最近更新:
适应症

试验速览

阶段
Unknown
状态
已完成
发起方
入组人数
12

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
N/a: Single Arm Study
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 45 Years(—)
性别
All

入选标准

  • Healthy male and female volunteers aged 18 to 45 years, with Body Mass Index (BMI) between 18.0 and 29.9 kg/m²

排除标准

  • Subjects fulfilling any of the following criteria are not eligible for inclusion in this study:
  • Current participation in any clinical study including the use of any investigational drugs at the time of enrolment, or within 5 half-lives of enrolment, whichever is longer; or longer if required by local regulations
  • weight less than 45 kg
  • any contraindications for MRI including but not limited to the following: any metal bearing implants (excluding dental retainer), cardiac pacemakers, brain aneurysm clip, implanted cardiac pacemaker, pacemaker wires or defibrillator, prosthetic heart valves, cochlear implant, ocular foreign body (e.g. metal shavings), implanted insulin pump, tattoos (as determined by imager) or claustrophobia
  • known allergic reactions or food intolerances to capsule materials or labelling agents
  • gastrointestinal diseases and/or pathological findings, which might interfere with gastrointestinal motility and emptying processes
  • drug or alcohol dependence
  • smokers of 10 or more cigarettes per day
  • subjects who are on a diet which could affect gastrointestinal motility (vegetarian, vegan)
  • eating disorders e.g. anorexia, bulimia
  • heavy tea or coffee drinkers (more than 1L per day)
  • lactating and pregnant women (positive urine test)
  • subjects suspected or known not to follow instructions
  • subjects who are unable to understand the written and verbal instructions, in particular regarding the risks and inconveniences they will be exposed to as a result of their participation in the study
  • history of orthostatic dysregulation, fainting, or blackouts
  • less than 2 weeks after last acute disease
  • less than 1 week after last blood donation
  • therapy with transdermal patches

研究者

发起方
Institut für Pharmazie - Biopharmazie und Pharmazeutische Technologie

相似试验